FDA — authorised 28 March 2022
- Application: NDA208088
- Marketing authorisation holder: VERITY
- Local brand name: TLANDO
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 LPCN 1021 in United States
FDA authorised LPCN 1021 on 28 March 2022
Marketing authorisation
Other Endocrinology approved in United States
Frequently asked questions
Is LPCN 1021 approved in United States?
Yes. FDA authorised it on 28 March 2022.
Who is the marketing authorisation holder for LPCN 1021 in United States?
VERITY holds the US marketing authorisation.